Merck kicked off its cardiovascular “renaissance” on Tuesday after the FDA signed off on its newest drug, Winrevair. Merck stock jumped.

The post Merck’s Cardiovascular ‘Renaissance’ Is Here With The First Approval Of A $10 Billion Franchise appeared first on Investor’s Business Daily.